Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved]
Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the stria...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2020-07-01
|
| Series: | F1000Research |
| Online Access: | https://f1000research.com/articles/9-862/v1 |
| _version_ | 1819048434609422336 |
|---|---|
| author | Thomas B Stoker Roger A Barker |
| author_facet | Thomas B Stoker Roger A Barker |
| author_sort | Thomas B Stoker |
| collection | DOAJ |
| description | Parkinson’s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials. |
| first_indexed | 2024-12-21T11:16:12Z |
| format | Article |
| id | doaj.art-d0c8cdf3318f4638bf01f79093da20a5 |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-21T11:16:12Z |
| publishDate | 2020-07-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-d0c8cdf3318f4638bf01f79093da20a52022-12-21T19:05:55ZengF1000 Research LtdF1000Research2046-14022020-07-01910.12688/f1000research.25634.128292Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved]Thomas B Stoker0Roger A Barker1John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Forvie Site, Robinson Way, Cambridge, CB2 0PY, UKWellcome Trust – Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, UKParkinson’s disease (PD) is a common neurodegenerative disease typified by a movement disorder consisting of bradykinesia, rest tremor, rigidity, and postural instability. Treatment options for PD are limited, with most of the current approaches based on restoration of dopaminergic tone in the striatum. However, these do not alter disease course and do not treat the non-dopamine-dependent features of PD such as freezing of gait, cognitive impairment, and other non-motor features of the disorder, which often have the greatest impact on quality of life. As understanding of PD pathogenesis grows, novel therapeutic avenues are emerging. These include treatments that aim to control the symptoms of PD without the problematic side effects seen with currently available treatments and those that are aimed towards slowing pathology, reducing neuronal loss, and attenuating disease course. In this latter regard, there has been much interest in drug repurposing (the use of established drugs for a new indication), with many drugs being reported to affect PD-relevant intracellular processes. This approach offers an expedited route to the clinic, given that pharmacokinetic and safety data are potentially already available. In terms of better symptomatic therapies that are also regenerative, gene therapies and cell-based treatments are beginning to enter clinical trials, and developments in other neurosurgical strategies such as more nuanced deep brain stimulation approaches mean that the landscape of PD treatment is likely to evolve considerably over the coming years. In this review, we provide an overview of the novel therapeutic approaches that are close to, or are already in, clinical trials.https://f1000research.com/articles/9-862/v1 |
| spellingShingle | Thomas B Stoker Roger A Barker Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] F1000Research |
| title | Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] |
| title_full | Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] |
| title_fullStr | Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] |
| title_full_unstemmed | Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] |
| title_short | Recent developments in the treatment of Parkinson's Disease [version 1; peer review: 2 approved] |
| title_sort | recent developments in the treatment of parkinson s disease version 1 peer review 2 approved |
| url | https://f1000research.com/articles/9-862/v1 |
| work_keys_str_mv | AT thomasbstoker recentdevelopmentsinthetreatmentofparkinsonsdiseaseversion1peerreview2approved AT rogerabarker recentdevelopmentsinthetreatmentofparkinsonsdiseaseversion1peerreview2approved |